Treatment Approaches for Amyotrophic Lateral Sclerosis
Conventional Therapies and Innovative Solutions
DOI:
https://doi.org/10.58445/rars.1489Keywords:
Amyotrophic Lateral Sclerosis, ALS, Therapies, TreatmentsAbstract
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease that impairs motor neuron function, causing progressive muscle weakness and paralysis. ALS is extremely rare, affecting only around 30,000 people in the United States. However, it has a very low survival rate; only 10% of patients survive 10 years after disease onset. While the cause is typically unknown, 5-10% of ALS cases are caused by genetic mutations in the SOD1 and C9orf72 genes. Currently, several FDA-approved therapies for ALS exist. These drugs aim to partially correct the SOD1 mutation, or block cellular and neurological pathways related to motor neuron damage. In clinical studies to date, these drugs either unsuccessfully treat ALS, or are only able to prolong a patient's lifespan up to several months. Scientists are exploring novel therapies that target the root cause of ALS, whether it be damaged neurons, genetic factors, or muscle dysfunction. These therapies include gene therapy, monoclonal antibody therapy, and stem cell therapy. While further research is needed, current data show significant promise, as these treatments directly target the underlying mechanisms of ALS, rather than focusing on select symptoms like conventional approaches, ultimately making new approaches to ALS therapy more sustainable for the future. This paper will discuss and evaluate current FDA-approved therapies for ALS and explore the potential efficacy of novel treatments.
References
The ALS Association. (2021, April 26). What is ALS? The ALS Association; The ALS Association. https://www.als.org/understanding-als/what-is-als
What Is the Prevalence of ALS? (2023, October 12). Healthline. https://www.healthline.com/health/als-prevalence#:~:text=It
Stages of ALS | The ALS Association. (n.d.). Www.als.org. Retrieved July 14, 2024, from https://www.als.org/understanding-als/stages#:~:text=And%2C%20while%20the%20average%2
ALS Association. (2021). FDA-Approved Drugs. The ALS Association. https://www.als.org/navigating-als/living-with-als/fda-approved-drugs
FDA-Approved Drugs for Treating ALS | The ALS Association. (n.d.). Www.als.org. Retrieved July 14, 2024, from https://www.als.org/navigating-als/living-with-als/fda-approved-drugs#:~:text=There%20are%20
Tzeplaeff, L., Wilfling, S., Requardt, M. V., & Herdick, M. (2023). Current State and Future Directions in the Therapy of ALS. Cells, 12(11), 1523. https://doi.org/10.3390/cells12111523
Is ALS Genetic? | The ALS Association. (n.d.). Www.als.org. https://www.als.org/understanding-als/who-gets-als/familial#:~:text=ALS%20is%20similar%20whether%20it
ALS Genes and Mutations. (n.d.). The ALS Association. https://www.als.org/research/als-research-topics/genetics
Tofersen. (n.d.). The ALS Association. https://www.als.org/navigating-als/living-with-als/fda-approved-drugs/tofersen
MS, M. W. (n.d.). The stages of amyotrophic lateral sclerosis (ALS) | ALS News Today. Alsnewstoday.com. Retrieved July 14, 2024, from https://alsnewstoday.com/stages-of-als/#:~:text=ALS%20progression%20timeline&text=While%
Zarei, S., Carr, K., Reiley, L., Diaz, K., Guerra, O., Altamirano, P., Pagani, W., Lodin, D., Orozco, G., & Chinea, A. (2015). A comprehensive review of amyotrophic lateral sclerosis. Surgical Neurology International, 6(1), 171. https://doi.org/10.4103/2152-7806.169561
Edaravone. (n.d.). The ALS Association. https://www.als.org/navigating-als/living-with-als/fda-approved-drugs/edaravone
Cleveland Clinic. (2022, April 25). Gamma-Aminobutyric acid (GABA). Cleveland Clinic. https://my.clevelandclinic.org/health/articles/22857-gamma-aminobutyric-acid-gaba
Mattson, M. P. (2019). Excitotoxicity - an overview | ScienceDirect Topics. Www.sciencedirect.com. https://www.sciencedirect.com/topics/neuroscience/excitotoxicity
Foran, E., & Trotti, D. (2009). Glutamate Transporters and the Excitotoxic Path to Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis. Antioxidants & Redox Signaling, 11(7), 1587–1602. https://doi.org/10.1089/ars.2009.2444
Glutamate - The ALS Association. (n.d.). Web.alsa.org. http://web.alsa.org/site/PageServer?pagename=ALSA_Glutamate
Fang, T., Al Khleifat, A., Meurgey, J.-H., Jones, A., Leigh, P. N., Bensimon, G., & Al-Chalabi, A. (2018). Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. The Lancet Neurology, 17(5), 416–422. https://doi.org/10.1016/s1474-4422(18)30054-1
MS, M. W. (2019, November 26). Riluzole for ALS in Dissolving Oral Film Form, Called Exservan, Approved by FDA. Alsnewstoday.com. https://alsnewstoday.com/news/fda-approves-exservan-riluzole-dissolving-oral-film-for-als/
Tiglutik – Thickened Liquid Riluzole – Receives FDA Approval to Treat ALS. (n.d.). The ALS Association. https://www.als.org/blog/tiglutik-thickened-liquid-riluzole-receives-fda-approval-treat-als
Food and Drug Administration. (2018, July 25). What Is Gene Therapy? FDA; FDA. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/what-gene-therapy
Fang, T., Je, G., Pacut, P., Keyhanian, K., Gao, J., & Ghasemi, M. (2022). Gene Therapy in Amyotrophic Lateral Sclerosis. Cells, 11(13), 2066. https://doi.org/10.3390/cells11132066
Monoclonal antibody drugs for cancer: How they work. (n.d.). Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/cancer/in-depth/monoclonal-antibody/art-20047808#:~:text=Your%20body%20keeps%20your%20immune
Monoclonal antibody shows promise in slowing progression of ALS. (2023, July 31). News-Medical. https://www.news-medical.net/news/20230731/Monoclonal-antibody-shows-promise-in-slowing-progression-of-ALS.aspx
Ozanezumab Overview - Creative Biolabs. (n.d.). Www.creativebiolabs.net. https://www.creativebiolabs.net/ozanezumab-overview.htm
Meininger, V., Genge, A., van den Berg, L. H., Robberecht, W., Ludolph, A., Chio, A., Kim, S. H., Leigh, P. N., Kiernan, M. C., Shefner, J. M., Desnuelle, C., Morrison, K. E., Petri, S., Boswell, D., Temple, J., Mohindra, R., Davies, M., Bullman, J., Rees, P., & Lavrov, A. (2017). Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Neurology, 16(3), 208–216. https://doi.org/10.1016/s1474-4422(16)30399-4
MedlinePlus. (2016, March 29). Stem Cells. Medlineplus.gov. https://medlineplus.gov/stemcells.html#:~:text=Stem%20cells%20are%20cells%20with
Tomlin, C. (2023, November 17). Regenerative Medicine: A New Path for ALS Treatment. Cedars-Sinai. https://www.cedars-sinai.org/discoveries/a-new-path-for-als-treatment.html
Downloads
Posted
Categories
License
Copyright (c) 2024 Srishti Iyer, Lananh Ho
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.